

## DAFTAR PUSTAKA

1. Adeoye P, Johnson W, Desalu O, Ofoegbu C, Fawibe A, Salami A, et al. Etiology, clinical characteristics, and management of pleural effusion in Ilorin, Nigeria. *Nigerian Medical Journal*. 2017;58(2):76-80.
2. Puspita I, Umiana Soleha T, Berta G. Penyebab Efusi Pleura di Kota Metro pada tahun 2015. *J Agromed Unila* 2017; 4(1): 25-33.
3. Shi HZ, Liang QL, Jiang J, Qin XJ, Yang HB. Diagnostik value of carcinoembryonic antigen in malignant pleural effusion: A meta-analysis. *Respirology*. 2008;13(4):518-27.
4. Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang HB. Diagnostik accuracy of tumor markers for malignant pleural effusion: A meta-analysis. *Thorax*. 2008; 63(1):35-41.
5. Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y. Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy. Vol. 7, *Cancer Medicine*. Blackwell Publishing Ltd; 2018. p. 6124-36.
6. Wulaningsih W, Holmberg L, Garmo H, Malmstrom H, Lambe M, Hammar N, et al. Serum lactate dehydrogenase and survival following cancer diagnosis. *Br J Cancer*. 2015;113(9):1389-96.
7. Puspa R, Widirahardjo, Syarani F, Mutiara E. Akurasi Diagnostik Pemeriksaan Kadar Adenosine Deaminase Cairan Pleura pada Efusi Pleura Tuberkulosis. *J Respir Indo*. 2017; 37(4) : 1-5.
8. Verma A, Abisheganaden J, Light RW. Identifying Malignant Pleural Effusion by A Cancer Ratio (Serum LDH: Pleural Fluid ADA Ratio). *Lung*. 2016;194(1):147-53.
9. Prasenohadi, Nita C, Andhika C, Fadlika H, Fariz N. *J Nat Sc Biol Med*. 2022; 13(1):45-51.
10. Charalampidis C, Youroukou A, Lazaridis G, Baka S, Mpoukovinas I, Karavasilis V, et al. Physiology of the pleural space. *J Thorac Dis*. 2015.18(1):7-33.
11. Light RW. Anatomy of the pleura. In: Light RW. *Textbook of Pleural Diseases* , 2<sup>nd</sup> ed. London: Hodder & Stoughton Ltd; 2008.p.13-24.
12. Light RW, Erozan YS, Ball WC. Cells in pleural fluid. Their value in differential diagnosis. *Arch intern Med*. 1973;132(4): 854-60.
13. Samanta S, Sharma A, Das B, Mallick AK, Kumar A. Significance of total protein, albumin, globulin, serum effusion albumin gradient and LDH in the differential diagnosis of pleural effusion secondary to tuberculosis and cancer. *Journal of*

Clinical and Diagnostik Research. 2016;10(8):8-14.

14. Skok K, Hladnik G, Grm A, Crnjac A. Malignant pleural effusion and its current management : A review. *Med*. 2019; 55(8):1-21.
15. Light RW, Macgregor MI, Luchsinger PC, Ball WC. Pleural effusions the diagnostik separation of transudates and exudates. *Ann Intern Med*. 1972; 77(1): 507-13.
16. Beaudoin S, Gonzalez A v. Evaluation of the patient with pleural effusion. Vol.190, *CMAJ*. Canadian Medical Association. 2018. 5-29.
17. Yalcin NG, Choong CKC, Eizenberg N. Anatomy and Pathophysiology of the Pleura and Pleural Space. *Thoracic Surgery Clinics*. 2013; 23: 1–10.
18. Wang J, Liu J, Xie X, Shen P, He J, Zeng Y. The pleural fluid lactate dehydrogenase/adenosine deaminase ratio differentiates between tuberculosis and parapneumonic pleural effusions. *BMC Pulm Med*. 2017; 17(168): 2-6.
19. Syahrudin E, Hudoyo A, Arief N. Efusi Pleura Ganas Pada Kanker Paru. *Jurnal Respirologi*. 2009; 29(4):1–9.
20. Desai NR, Lee HJ. Diagnosis and management of malignant pleural effusions: State of the art in 2017. *Journal of Thoracic Disease*. AME Publishing Company; 2017; 9: 1111–22.
21. Antony VB. Immunological mechanisms in pleural disease. *European Respiratory Journal*. European Respiratory Society; 2003; 21: 539–44.
22. Ye ZJ, Zhou Q, Yuan ML, Du RH, Yang WB, Xiong XZ, et al. Differentiation and recruitment of IL-22-producing helper T cells stimulated by pleural mesothelial cells in tuberculous pleurisy. *Am J Respir Crit Care Med*. 2012;185(6):660–9.
23. Ye ZJ, Zhou Q, Yin W, Yuan ML, Yang WB, Xiang F, et al. Interleukin 22-producing CD4+ T cells in malignant pleural effusion. *Cancer Lett*. 2012; 326(1):23–32.
24. Scherpereel A, Grigoriu BD, Noppen M, Gey T, Chahine B, Baldacci S, et al. Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid. *BMC Cancer*. 2013;13(1): 324-30.
25. Pace E, di Sano C, Ferraro M, Tipa A, Olivieri D, Spatafora M, et al. Altered CD94/NKG2A and perforin expression reduce the cytotoxic activity in malignant pleural effusions. *Eur J Cancer*. 2011; 47(2):296–304.
26. Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: Tumor-host interactions unleashed. *American Journal of Respiratory and Critical Care Medicine*. 2012; 186:487–92.

27. Stathopoulos GT, Sherrill TP, Karabela SP, Goleniewska K, Kalomenidis I, Roussos C, et al. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. *Am J Respir Crit Care Med*. 2010;182(10):1273–81.
28. Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, Pitsinos EN, et al. Tumor necrosis factor- $\alpha$  promotes malignant pleural effusion. *Cancer Res*. 2007; 67(20): 9825–34.
29. Jongsma J, van Montfort E, Vooijs M, Zevenhoven J, Krimpenfort P, van der Valk M, et al. A Conditional Mouse Model for Malignant Mesothelioma. *Cancer Cell*. 2008;13(3):261–71.
30. Agalioti T, Giannou AD, Krontira AC, Kanellakis NI, Kati D, Vreka M, et al. Mutant KRAS promotes malignant pleural effusion formation. *Nature Communications*. 2017; 8(15205):1-15.
31. Porcel JM. Biomarkers in the diagnosis of pleural diseases: a 2018 update. *Therapeutic Advances in Respiratory Disease*. SAGE Publications Ltd; 2018;12(3):1-11.
32. Porporato P, Dadhich R, Dhup S, Sonveaux P, Anticancer Targets in the Glycolytic Metabolism of Tumors. 2011; 2(49) : 1-19.
33. Forkasiewicz A, Dorociak M, Stach K, Szelachowski, Tabola R, Augoff K, The usefulness of lactate dehydrogenase measurements in current oncological practice. *Cellular & Molecular Biology Letters*. 2020; 25(35) : 1-14.
34. Fantin VR, St Pierre, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. *Cancer Cell*. 2006; 9(4):425–34.
35. Tarn AC, Lapworth R. Biochemicals analysis of pleural fluid: what should we measure? Review article. *Ann Clin Biochem*.2001;38(5): 311-22.
36. Hugo Carmona, Stephen Allison, Matthew Triplette, Rosemary Adamson. Transthoracic Needle Biopsy. *Am J Respir Crit Care Med*. 2021; 204(3): 31-5.
37. Saldana RB, Nava RU, Rojas AE, Gonzalez PC, Duenas SL, Perez TA, et al. Accuracy of closed pleural biopsy in the diagnosis of malignant pleural effusion. *J Bras Pneumol*. 2017; 43(6):424-30.
38. Zafer A, Ersin G, Nevin T, Aydin Y, Funda D, Sibel G, et al. Endobronchial cryobiopsy or forceps biopsy for lung cancer diagnosis. *Annals of Thoracic Medicine*. 2010; 5(4):243–6.
39. Fan Z, Lijuan H, Wang J, Jian C, Jie C, Yumin W. Clinical value of jointly detection serum lactate dehydrogenase/pleural fluid adenosine deaminase and pleural fluid carcinoembryonic antigen in the identification of malignant pleural effusion. *J Clin Lab Anal*. 2017; 31(4):1-4.

40. Tian P, Qiu R, Wang M, Xu S, Cao L, Yang P, et al. Prevalences, Causes, and Health Care Burden of Pleural Effusions Among Hospitalized Adults in China. *JAMA Netw Open*. 2021; 4(8):1-9.
41. Ryan H, Trosclair A, Gfroerer J. Adult current smoking: Differences in definitions and prevalence estimates NHIS and NSDUH. *J Environ Public Health*. 2012; 2012 (2): 1-11.
42. Kramarrow AE. Health of Former Cigarette Smokers Aged 65 and Over: United States, 2018. *National Health Statistics Reports*. 2020; 145(7): 1-11.
43. Consonni D, Matteis SD, Lubin JH, Wacholder S, Tucker M, Pesatori AC, et al. Lung Cancer and Occupation in a Population based Case Control Study. *American Journal of Epidemiology*. 2010; 171(10): 323-33.
44. Dahlan S. *Penelitian Diagnostik (Dasar-dasar Teoritis dan Aplikasi dengan Program SPSS dan Stata)*. Edisi 1. Jakarta: Salemba Medika; 2009. hal.31-48.
45. Saguil A, Wyrick K, Hallgren J. Diagnostik Approach to Pleural Effusion. *Am Fam Physician*. 2014; 90(2):1-6.
46. Heffner J, Klein J. Recent advances in the diagnosis and management of malignant pleural effusions. *Mayo Clin Pro*. 2008 ; 83(2):235-50.
47. Zhang Y, Li X, Liu J, Hu X, Wan C, Zhang R, et al. Diagnostik accuracy of the cancer ratio for the prediction of malignant pleural effusion : evidence from a validation study and meta-analysis. *Annals of Medicine*. 2021; 53(1):558-66.
48. Dewi H, Fairuz. Karakteristik pasien efusi pleura di kota Jambi. *JMJ*. 2020;8:56-58
49. Yosefany N, Susilawati, Inggarsih R. Hubungan karakteristik klinis dan etiologi pada pasien efusi pleura di RSUP Dr. Mohammad Hoesin tahun 2019. *Jurnal Kedokteran dan Kesehatan: Publikasi Ilmiah Fakultas Kedokteran Universitas Sriwijaya*. 2022;9:247-251.
50. Ariansyah P, Maker I, Sumad J, Sriwidayani P. Profil Sitologi Efusi Pleura Maligna di RSUP Sanglah Tahun 2015-2017. *Jurnal Medika Udayana*. 2020 ;9(6): 44-8.
51. Adeoye PO, Jhonson WR, Desalu OO, Ofoegbu CP, Fawibe AE, Salami AK, et al. Etiology, clinical characteristics, and management of pleural effusion in Ilorin, Nigeria. *Nigerian Medical Journal*. 2017; 58(2):76-80.
52. Mangkouta S, Glynos K, Pappas A, Papapetropoulos A, Kalomenidis L. Effect of smoking on experimental malignant pleural effusion. *European Respiratory Journal*. 2015; 46(59):1-8.
53. Tian P, Qiu R, Wang M, Xu S, Cao L, Yang P, et al. Prevalence, Causes, and Health

Care Burden of Pleural Effusions Among Hospitalized Adults in China. *JAMA Network Open*. 2021; 4(8):1-5.

54. Marcelino AB, Tavares RJ, Marcelino KB, Neto JA. Breast cancer and occupational exposures: an integrative review of the literature. *Rev Bras Med Trab*. 2020;18(4):488-96.
55. Spyrtos D, Zarogoulidis P, Porpodis K, Tsakiridi K, Machairiotis N, Katsikogiannis N, et al. Occupational exposure and lung cancer. *J Thorac Dis*. 2013; 5(4):440-6.
56. Nikie D, Stankovic A. Air pollution as a risk factor for lung cancer. *Arch Oncol* 2005;13(2):79-82.
57. Ferigollo, Ariellen, Bazzan, Teichmann LS, Ceni, Cristina G, et al. Prevalence of malnutrition and factors associated with the nutritional status of oncological patients. *Nutr. clín. diet. hosp*. 2018; 38(4):137- 42.
58. Suarez SM, Santolaria F, Perez RA, Aleman MR, Martinez R, Gonzalez R, et al. Prognostic value of inflammatory markers (notably cytokines and procalcitonin), nutritional assessment, and organ function in patients with sepsis. *Eur Cytokine Netw*. 2010; 21(1):19-26.
59. Tredan O, Ray C, Chvetzoff G, Rebattu P, Bajard A, Chabaud S, et al. Validation of prognostic scores for survival in cancer patients beyond first line therapy. *BMC Cancer*. 2011; 11(95):1-9.
60. Terra RM, Antonangelo L, Mariani AW, Oliveira R, Texeira L, Fernandes P. Pleural Fluid Adenosine Deaminase (ADA) Predicts Survival in Patients with Malignant Pleural Effusion. *Lung*. 2016; 194(4):681-6.
61. Helmy NA, Eissa SA, Masoud HH, Elessawy AF, Ahmed RI. Diagnostic value of adenosine deaminase in tuberculous and malignant pleural effusion. *Egypt J Chest Dis Tuberc*. 2012; 61(4):413-7.
62. Pairman L, Beckert LE, Dagger Mark, Maze MJ. Evaluation of pleural fluid cytology for the diagnosis of malignant pleural effusion: a retrospective cohort study. *Internal Medicine Journal*. 2022; 52(7):1154-9.
63. He R, He S. Diagnostik availability (DA) based on phytagorean theorem as novel index for integrative evaluation of diagnostik test. *Journal of Medical Diagnostik Methods*. 2017;6(2):1-6.
64. Han YQ, Zhang L, Yan L, Ouyang PH, Li P, Hu ZD. Diagnostik accuracy of cancer ratio for malignant pleural effusion: a systematic review and meta-analysis. *Ann Transl Med*. 2019;7(20): 1-6.
65. Amalia R, Pradjoko I. Nilai Diagnostik Adenosine Deaminase (ADA) Cairan

Pleura pada Penderita Efusi Pleura Tuberkulosis: Jurnal Respirasi. 2016; 2(2):35-40.

66. ElSharawy DE, Hagra MM, Khedr RA. The clinical utility of joined detection of cancer ratio, cancer ratio plus, Interferon gamma (IFN-  $\gamma$ ) & Carcinoembryonic antigen (CEA) in differentiating lymphocytic pleural effusions : The Egyptian Journal of Bronchology. 2020; 14(3):1-6.
67. Anugraha. Evaluation of cancer ratio and cancer ratio plus in identifying malignant effusion from other exudative effusions – a prospective study : The Tamilnadu DR.

M.G.R. Medical University Chennai; 5(3):47-108.

